pre-IPO PHARMA

COMPANY OVERVIEW

CStone Pharmaceuticals is a biopharmaceutical company devoted to the development of a new generation of innovative drugs. With its broad immuno-oncology pipeline, CStone is pursuing a development strategy focusing on combination therapy. In July 2016, CStone Pharmaceuticals announced the completion of its $150 million Series A financing, led by three prestigious VC/PE funds: Oriza Seed Venture Capital, Boyu Capital and WuXi Healthcare Ventures.


LOCATION

  • Suzhou, , China

  • THERAPEUTIC AREAS

  • Immunology
  • Oncology

  • WEBSITE

    None


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    boyu-capital oriza-seed-venture-capital wuxi-healthcare-ventures


    PRESS RELEASES


    Jan 2, 2022

    CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in-class ROR1-targeting ADC by the U.S. Food and Drug Administration


    Dec 22, 2021

    Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy


    Nov 23, 2021

    CStone Pharmaceuticals y Jiangsu Hengrui Pharmaceuticals anuncian una alianza estratégica y un acuerdo de licencia exclusivo para anticuerpos monoclonales anti-CTLA-4 CS1002 en la Gran China Latin America - español España - español USA - English USA - English


    Nov 22, 2021

    CStone Pharmaceuticals und Jiangsu Hengrui Pharmaceuticals geben strategische Partnerschaft und exklusive Lizenzvereinbarung für den monoklonalen Anti-CTLA-4-Antikörper CS1002 in Greater China bekannt Deutschland - Deutsch España - español USA - English USA - English


    Nov 21, 2021

    CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China USA - English España - español USA - English


    For More Press Releases


    Google Analytics Alternative